<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147826">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01696487</url>
  </required_header>
  <id_info>
    <org_study_id>Fru1.0</org_study_id>
    <nct_id>NCT01696487</nct_id>
  </id_info>
  <brief_title>Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pilot Study.</brief_title>
  <official_title>Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Scientific Fund of the Mayor of the City of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The spectrum of NAFLD as emerging epidemic ranges from steatosis to steatohepatitis (NASH),
      cirrhosis and hepatocellular carcinoma (HCC). Disease progression is poorly understood and
      treatment options are limited. Fructose overconsumption has been associated with gut
      permeability and progression of NAFLD. To unravel the mechanisms of fructose-induced
      intestinal changes, volunteers will receive a 4-week fructose challenge prior to assessment
      of intestinal permeability/translocation using endomicroscopy, sugar probes, serum markers
      of intestinal damage, inflammation, iron/copper homeostasis and histological/molecular
      analysis of intestinal biopsies. Findings in volunteers will be compared with liver patients
      undergoing study procedures without fructose challenge. Translational in vitro experiments
      will explore cellular responses to fructose and endotoxin. This project should provide novel
      insights into dietary induced alterations of the gut integrity in progression of NAFLD to
      NASH.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Gaps per 1000 intestinal epithelial cells assessed by confocal laser endomicroscopy</measure>
    <time_frame>Time point 1 (day 1 - all study groups)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gaps per 1000 intestinal cells will be assesed during gastroscopy by confocal laser endomicroscopy at time point 1 in all study groups and after the 4 week fructose challange in healthy volunteers only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gaps per 1000 intestinal epithelial cells assessed by confocal laser endomicroscopy</measure>
    <time_frame>point 2 (week4/day28 - after fructose challange; healthy volunteers only)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gaps per 1000 intestinal cells will be assesed during gastroscopy by confocal laser endomicroscopy at time point 1 in all study groups and after the 4 week fructose challange in healthy volunteers only</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will be challenged with oral 150g Fructose per day for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAFLD</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with confirmed fatty liver (imaging positive) will be compared at baseline with other arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NASH</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with confirmed non-alcoholic steatohepatitis (biopsy proven) will be compared at baseline with other arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis C genotype 1 (HCV-GT1)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with confirmed hepatitis C genotype 1 will be compared at baseline with other arms and act as different liver disease control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High oral Fructose challenge (150g per day for 28 days)</intervention_name>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Healthy men and women from 18 to 85, no disease history, no intake of regular
             medication.

          2. Patients with confirmed (at least one imaging positive) intrahepatic fat accumulation
             (NAFL), male and female

          3. Patients with confirmed NASH (biopsy within 6 months prior to study), male and female

          4. Diagnosed HCV, genotype 1, male and female

        Signed informed consent

        General exclusion criteria (for all groups)

          1. Pregnancy and lactation

          2. Imprisoned persons

          3. Inflammatory bowel conditions (celiac disease, Crohn's disease, ulcerative colitis)

          4. Prior bariatric surgery

          5. Alcoholic steatohepatitis and/or alcohol consumption &gt; 140 gramms per week (or &gt;
             30g/day)

          6. Other liver diseases (autoimmune, genetic, cholestatic, Wilson disease,
             Weber-Christian disease, partial lipodystrophy of the face sparing type,
             abetalipoproteinemia, and jejunal diverticulosis with bacterial overgrowth.)

          7. Virus hepatitis (A, B, C) (except for group (4): defined as HCV, genotype 1)

          8. Known allergic reaction to the drugs used (see material and methods)

          9. Intake of drugs known to accumulate intrahepatic lipids (e.g.
             steroids/glucocorticoids, tamoxifen, amiodarone, perhexiline maleate, synthetic
             estrogens, antiretroviral agents, tetracycline, minocycline, certain pesticides,
             methotrexate)

         10. Intake of drugs known to drive fibrosis/cirrhosis (e.g. azathioprine, oral
             contraceptive pills)

         11. Inability or contraindications to perform study procedures

         12. General and absolute endoscopy contraindications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Trauner, Professor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Gastroenterology and Hepatology Department of Internal Medicine III Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Trauner, Professor, MD</last_name>
    <phone>+43140400</phone>
    <phone_ext>4741</phone_ext>
    <email>michael.trauner@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petra Munda, Associate Professor, MD</last_name>
    <phone>+43140400</phone>
    <phone_ext>4741</phone_ext>
    <email>petra.munda@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna, General Hospital of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Trauner, Professor, MD</last_name>
      <phone>+43140400</phone>
      <phone_ext>4741</phone_ext>
      <email>michael.trauner@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Petra Munda, Associate Professor, MD</last_name>
      <phone>+43140400</phone>
      <phone_ext>4741</phone_ext>
      <email>petra.munda@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Kienbacher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Werner Dolak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Traussnigg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 28, 2012</lastchanged_date>
  <firstreceived_date>September 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Prof. Michael Trauner, MD</investigator_full_name>
    <investigator_title>Professor, MD, Head and Chair of the Division of Gastroenterology and Hepatology, Department of Internal Medicine III</investigator_title>
  </responsible_party>
  <keyword>non-alcoholic fatty liver disease</keyword>
  <keyword>non-alcoholic steatohepatitis</keyword>
  <keyword>NAFLD</keyword>
  <keyword>NASH</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
